Report Scope: —
Antibody drug conjugates are mainly used to treat cancer and are safer and more effective than many other cancer therapies. This report focuses on the global market for antibody drug conjugate products and provides an updated review, including their basic design and application in various areas of the biomedical sciences. The report covers three main areas of application, breast cancer, lymphoma and other cancers, including acute myeloid leukemia. The scope of this study includes the current market for ADCs. The report also discusses regulatory aspects, current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations and opportunities and the latest trends in ADC market are also discussed in the report.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2820095-antibody-drug-conjugates-technologies-and-global-markets
Also included in the report is an analysis of relevant patents and profiles of companies that lead the antibody drug conjugate product market. Seattle Genetics Inc., Takeda Pharmaceuticals Co. Ltd. and Genentech Inc. are the major players in the market for ADCs at present.
Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis, and sales are broken down geographically into North America, Europe, Asia-Pacific and the emerging markets. The application of ADCs in various types of cancer is discussed from both a commercial perspective and that of a research and development (R&D) perspective.
The report only covers antibody drug conjugates in which an antibody is conjugated with small-molecule cytotoxins (payload) through a linker. ADCs are a form of antibody conjugates. Other forms of antibody conjugates such as radioisotope conjugated with an antibody are beyond the scope of this report. The study also does not cover mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC.
- An overview of the global market for antibody drug conjugates as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
ABGENOMICS INTERNATIONAL INC.
ADC BIOTECHNOLOGY LTD.
ADC THERAPEUTICS SA
ANTIKOR BIOPHARMA LTD.
ASTELLAS PHARMA U.S. INC.
CATALENT PHARMA SOLUTIONS
CELLDEX THERAPEUTICS INC.
CYTOMX THERAPEUTICS INC.
DAIICHI SANKYO CO. LTD.
DALTON PHARMA SERVICES
ELI LILLY AND CO.
ESPERANCE PHARMACEUTICALS INC.
F. HOFFMANN-LA-ROCHE AG (ROCHE)
HEIDELBERG PHARMA GMBH
MERSANA THERAPEUTICS INC.
MILLENNIUM PHARMACEUTICALS INC. (NOW TAKEDA ONCOLOGY)
PROGENICS PHARMACEUTICALS INC.
SEATTLE GENETICS INC.
SORRENTO THERAPEUTICS INC.
SUTRO BIOPHARMA INC.
VIVENTIA BIOTECHNOLOGIES INC.
ZHEJIANG MEDICINE CO. LTD.
Table of Content: Key Points
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Chapter 4 Market Breakdown by Technology Type
Chapter 5 Market Breakdown by Application
Chapter 6 Industry Structure
Chapter 7 Market Breakdown by Region
Chapter 8 Patent Review/New Developments
Chapter 9 Analysis of Market Opportunities
Chapter 10 Company Profiles
ACCESS REPORT @ https://www.wiseguyreports.com/reports/2820095-antibody-drug-conjugates-technologies-and-global-markets
Get in touch:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042
Release ID: 293213